Surrey Heartlands

Joint Formulary & PAD

Sildenafil (Erectile Dysfunction) - Erectile dysfunction

You are here : Home > Formulary Search > Sildenafil (Erectile Dysfunction) - Erectile dysfunction

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Preferred
 

Status 2

See narrative
Formulations :
  • Orodispersible films
  • Oromucosal spray
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
NFD2
SPC
Restrictions / Comments :
Important

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

Documentation

Information
Sildenafil SLS restrictions removed for generic sildenafil
Information
Erectile dysfunction - traffic light status updates - Jun 2024

PAD Profile

ChemicalSubstance :
Sildenafil (Erectile Dysfunction)
Indication :
Erectile dysfunction
Group Name :
Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence, PDE5, PDE-5
Brand Names Include :
Viagra, Nipatra, Silandyl
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Erectile dysfunction
Supporting Documents :
2
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Sildenafil (Erectile Dysfunction) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Erectile dysfunction.

Committee Recommendations (2)

04 Jun 25 - Not Set

This sildenafil formulation (orodispersible film) has not yet been assessed for formulary status and is not currently on the APC work-plan.

It has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

Before prescribing this drug, it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

05 Jun 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC have updated the recommended treatment options for erectile dysfunction.

Sildenafil remains a preferred treatment option.

Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use.